Wattanachayakul Phuuwadith, Srikulmontri Thitiphan, Prasitsumrit Vitchapong, Suenghataiphorn Thanathip, Danpanichkul Pojsakorn, Polpichai Natchaya, Saowapa Sakditad, Idowu Abiodun, Amanullah Aman
Department of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USA.
Sidney Kimmel Medical College, Thomas Jefferson University Philadelphia Pennsylvania USA.
J Arrhythm. 2024 Jul 16;40(4):975-981. doi: 10.1002/joa3.13116. eCollection 2024 Aug.
Cardiovascular and noncardiovascular comorbidities have been recognized as predictors of clinical response in patients receiving cardiac resynchronization therapy (CRT). However, data on vitamin D as a predictor of CRT response are conflicting.
We identified studies from MEDLINE and Embase databases, searching from inception to May 2024, to investigate the association between 25-OH vitamin D levels before CRT implantation and outcomes. Studies had to report 25-OH vitamin D levels or the proportion of patients with vitamin D insufficiency and categorize outcomes as CRT responders or nonresponders. We extracted mean 25-OH vitamin D and standard deviations for both groups from each study and calculated the pooled mean difference (MD). We also retrieved risk ratios, and 95% confidence intervals (CIs) for the association between vitamin D insufficiency and lack of CRT response, combining them using the generic inverse variance method.
Our meta-analysis included four studies. CRT responders had higher levels of 25-OH vitamin D than nonresponders, with a pooled MD of 8.04 ng/mL (95% CI: 3.16-12.93; = 48%, < .001). Patients with vitamin D insufficiency before implantation had higher odds of lacking response to CRT, with a pooled RR of 3.28 (95% CI: 1.43-7.50; = 0%, = .005) compared to those with normal vitamin D.
CRT responders had higher 25-OH vitamin D levels compared to nonresponders. Vitamin D insufficiency was associated with a higher risk of nonresponse to CRT. These findings highlight the importance of monitoring and managing vitamin D levels in these patients.
心血管和非心血管合并症已被公认为是接受心脏再同步治疗(CRT)患者临床反应的预测指标。然而,关于维生素D作为CRT反应预测指标的数据存在矛盾。
我们从MEDLINE和Embase数据库中检索了从数据库建立至2024年5月的研究,以调查CRT植入前25-羟维生素D水平与治疗结果之间的关联。研究必须报告25-羟维生素D水平或维生素D不足患者的比例,并将结果分为CRT反应者或无反应者。我们从每项研究中提取两组的平均25-羟维生素D和标准差,并计算合并平均差(MD)。我们还检索了维生素D不足与CRT无反应之间关联的风险比和95%置信区间(CI),使用通用逆方差法进行合并。
我们的荟萃分析纳入了四项研究。CRT反应者的25-羟维生素D水平高于无反应者,合并MD为8.04 ng/mL(95%CI:3.16-12.93;I² = 48%,P <.001)。植入前维生素D不足的患者对CRT无反应的几率更高,与维生素D正常的患者相比,合并RR为3.28(95%CI:1.43-7.50;I² = 0%,P =.005)。
与无反应者相比,CRT反应者的25-羟维生素D水平更高。维生素D不足与CRT无反应的较高风险相关。这些发现凸显了监测和管理这些患者维生素D水平的重要性。